ABOUT ACTEMRA

Across multiple studies, multiple
endpoints and multiple patient types,

ACTEMRA Monotherapy:
Consistent results

in DMARD-IR and TNF-IR RA patients
Many biologics work best with MTX, but evidence suggests that certain patients need a different approach to therapy
  • ACTEMRA Monotherapy:
    Consistent efficacy across multiple studies.
  • ACTEMRA Monotherapy delivered rapid
    improvement and increasing response
  • ACTEMRA has a consistent safety
    profile shown study after study
  • Risk of serious infection, some patients have experienced serious infections when taking Actemra. Please see Important Safety Information below.
X